Cortexyme provides regulatory update on development program for atuzaginstat in alzheimer's disease

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company focused on alzheimer's and other degenerative diseases, received a letter from the u.s. food and drug administration (fda) stating that a partial clinical hold has been placed on atuzaginstat (cor388) impacting the open-label extension (ole) phase of the company's ongoing phase 2/3 study, the gain trial. under the hold, no new participants will be enrolled in the ole and curr
QNCX Ratings Summary
QNCX Quant Ranking